Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00 at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE - Free Report) had its price objective boosted by Canaccord Genuity Group from $13.00 to $16.00 in a research note issued to investors on Tuesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other brokerages have also recently commented on NAGE. Roth Capital reaffirmed a "buy" rating and issued a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Wall Street Zen downgraded Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th.

Niagen Bioscience Trading Down 1.8%

Shares of NASDAQ:NAGE traded down $0.26 during mid-day trading on Tuesday, hitting $13.88. The stock had a trading volume of 483,630 shares, compared to its average volume of 855,051. The firm's 50 day simple moving average is $9.11. Niagen Bioscience has a 12-month low of $2.31 and a 12-month high of $14.49. The stock has a market capitalization of $1.09 billion, a P/E ratio of 81.65 and a beta of 2.08.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.